RxDoctor Payments Data

Pierre Elias, MD

Cardiovascular Disease · New York, NYNPI 1770947418

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $8,294 of the $8,336 with a category attached, or 99.5%. GE HealthCare accounts for 99.5% of it on its own, with 1 other manufacturer making up the rest.

$8,336in general payments, 2019–2025

Across 3 payments — averaging $2778.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$8K
  • Edwards Lifesciences$42
$117,048in research payments, 2019–2025

Across 3 payments — averaging $39,016 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Edwards Lifesciences$84K
  • Janssen Research & Development, LLC$34K

What the payments were for

  • Speaking & faculty fees$8,294100%
  • Food & beverage$420%

General payments by program year

23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GE HealthCare2$8,294
Edwards Lifesciences1$42

How this compares

$8,336 in reported general payments places this provider in the 80th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$12,544
Medicare patients
23
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other cardiovascular disease in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →